UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
Profile & Fundamentals
UCB: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
UCB Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Company profile record
UCB SA
Common Stock · Health Care · Pharmaceuticals
Company
- Company / asset
- UCB SA
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Pharmaceuticals
- HQ
- 🇧🇪 Belgium
- Head office
- Allée de la Recherche, 60, Brussels, Belgium, 1070
Leadership & scale
- Chief executive
- Dr. Jean-Christophe Tellier
- CEO year born
- 1959
- Full-time employees
- 9K
- Fiscal year end
- December
Fundamentals snapshot
- Market Cap
- EUR 38.4B
- P/E
- 10.9x
- Revenue (Q2 26)
- EUR 4.3B
- Profit (Q2 26)
- EUR 1.1B
- Dividend Yield
- 0.9%
- Revenue (FY 25)
- EUR 7.7B
- Shares in public float
- 120.2M
- Insider ownership
- 36.28%
Reporting & identifiers
- Symbol
- UCB.BRU
- Listing
- 🇧🇪 Belgium | Dividend Tax: 30%
- Ticker Currency
- EUR
- Income Statement Currency
- EUR
- Balance Sheet Currency
- EUR
- Cash Flow Currency
- EUR
- EPS Currency
- EUR
- Contract Type
- SPOT
- ISIN
- BE0003739530
- Asset ID
- equity_e159b6d2-aa08-54db-9484-af8443d74188
Ownership
Shares Outstanding
Latest: 190.0M | Max: 199.6M | Min: 188.3M
Latest reported ownership snapshot
As of Oct 1, 2026Float Shares
63.24%
120.2M latest reported shares
Insider Ownership
36.28%
Latest reported insider stake
Short Float
--
Latest reported short interest / float
Source tablesView ownership tables
Shares Outstanding
Annual reported shares outstanding; up to 10 reporting dates.
Scroll the table to see every column.
| Reporting date | Shares outstanding |
|---|---|
| 2017-01-01 | 188,309,100 |
| 2018-01-01 | 188,484,000 |
| 2019-01-01 | 188,583,000 |
| 2020-01-01 | 199,604,200 |
| 2021-01-01 | 193,883,700 |
| 2022-01-01 | 192,175,900 |
| 2023-01-01 | 199,618,200 |
| 2024-01-01 | 194,435,600 |
| 2025-01-01 | 189,997,000 |
| 2026-01-01 | 189,997,000 |
Top Holders
Available reported ownership records.
No reported records are available in this preview.
Earnings, Profitability & Valuation
Earnings, Profitability & Valuation
Earnings & Revenue
Earnings and Revenue Trajectory
AI Review
UCB's financial performance demonstrates an operational turnaround as new growth therapies reach commercial scale. Full-year 2025 revenue grew 25.8% to 7.74 billion euros, while first-half 2026 revenue expanded another 22.5% to 4.27 billion euros. Strong prescription uptake for flagship immunology and rare disease products is comfortably overcoming generic erosion from older off-patent medicines. However, retail investors must understand that headline profits currently run ahead of actual cash collection. While first-half 2026 net income jumped to 1.11 billion euros, cash generation was tempered by rising customer receivables and inventory buildup. The business is fundamentally strengthening, but reported earnings reflect accounting gains before cash is fully realized.
UCB's financial performance demonstrates an operational turnaround as new growth therapies reach commercial scale. Full-year 2025 revenue grew 25.8% to 7.74 billion euros, while first-half 2026 revenue expanded another 22.5% to 4.27 billion euros. Strong prescription uptake for flagship immunology and rare disease products is comfortably overcoming generic erosion from older off-patent medicines. However, retail investors must understand that headline profits currently run ahead of actual cash collection. While first-half 2026 net income jumped to 1.11 billion euros, cash generation was tempered by rising customer receivables and inventory buildup. The business is fundamentally strengthening, but reported earnings reflect accounting gains before cash is fully realized.
Revenue, Net Income, and Free Cash Flow
Latest: EUR 7.7B | Max: EUR 7.7B | Min: EUR 319.0M
Valuation
P/E Ratio (TTM)iPublished valuation snapshots use the earnings basis recorded with each observation. Source tables retain that basis.
Latest: 17x
Profitability & Margins
Margins and Operating Efficiency
AI Review
Profit margins are undergoing a structural expansion as expensive, patent-protected biologics displace older chemical drugs. Gross margin held firmly above 71% in 2025 and widened toward 82% in first-half 2026, driven by high manufacturing efficiency and the rapid growth of high-margin specialty treatments. Adjusted operating margins reached an impressive 40.7% in early 2026, though management caution suggests this was temporarily boosted by favorable rebate accounting. As UCB broadens patient access in the United States, mandatory insurance discounts will moderate future realized prices. Overall profitability will comfortably exceed historical company averages as fixed commercial expenses spread over expanding sales.
Profit margins are undergoing a structural expansion as expensive, patent-protected biologics displace older chemical drugs. Gross margin held firmly above 71% in 2025 and widened toward 82% in first-half 2026, driven by high manufacturing efficiency and the rapid growth of high-margin specialty treatments. Adjusted operating margins reached an impressive 40.7% in early 2026, though management caution suggests this was temporarily boosted by favorable rebate accounting. As UCB broadens patient access in the United States, mandatory insurance discounts will moderate future realized prices. Overall profitability will comfortably exceed historical company averages as fixed commercial expenses spread over expanding sales.
Profitability Margins
Latest: 71.1% | Max: 74.1% | Min: 6.5%
Latest Profitability Ratios as of 2025-12-31
Gross Margin
71.1%
Gross profit / revenue
Operating Margin
15.1%
Operating income / revenue
Net Margin
20.1%
Net income / revenue
FCF Margin
24.3%
Free cash flow / revenue
Source tablesView earnings, profitability & valuation tables
Revenue, Net Income, and Free Cash Flow
Annual reported results, using the source statement's recorded USD conversion. Up to 10 reporting periods; missing values are not estimated.
Scroll the table to see every column.
| Period end | Revenue (USD) | Net income (USD) | Free cash flow (USD) |
|---|---|---|---|
| 2016-12-31 | 4,395,820,000 | 551,200,000 | 338,140,000 |
| 2017-12-31 | 5,324,060,000 | 896,070,000 | 984,130,000 |
| 2018-12-31 | 5,280,480,000 | 912,000,000 | 1,134,300,000 |
| 2019-12-31 | 5,502,560,000 | 887,040,000 | 658,560,000 |
| 2020-12-31 | 6,523,340,000 | 893,040,000 | 893,040,000 |
| 2021-12-31 | 6,585,780,000 | 1,206,120,000 | 1,208,400,000 |
| 2022-12-31 | 5,903,190,000 | 447,260,000 | 800,360,000 |
| 2023-12-31 | 5,777,200,000 | 377,300,000 | 489,500,000 |
| 2024-12-31 | 6,398,080,000 | 1,107,600,000 | 956,800,000 |
| 2025-12-31 | 9,056,970,000 | 1,822,860,000 | 2,201,940,000 |
Published P/E Ratio
Published valuation snapshots retain each observation's earnings basis.
Scroll the table to see every column.
| Period end | P/E (times earnings) | Earnings basis |
|---|---|---|
| 2025-12-31 | 17.28 | Trailing four quarters |
| 2024-12-31 | 26.54 | Trailing four quarters |
| 2022-12-31 | 33.82 | Annual net income |
| 2021-12-31 | 18.39 | Annual net income |
Profitability Margins
Matching annual reporting dates. Values are percentages.
Scroll the table to see every column.
| Period end | Gross margin (%) | Operating margin (%) | Net margin (%) | Free cash flow margin (%) |
|---|---|---|---|---|
| 2016-12-31 | 71.02 | 19.19 | 12.54 | 7.69 |
| 2017-12-31 | 73.18 | 24.03 | 16.83 | 18.48 |
| 2018-12-31 | 74.14 | 24.01 | 17.27 | 21.48 |
| 2019-12-31 | 70.95 | 22.06 | 16.12 | 11.97 |
| 2020-12-31 | 71.24 | 18.27 | 13.69 | 13.69 |
| 2021-12-31 | 72.1 | 19.85 | 18.31 | 18.35 |
| 2022-12-31 | 66.23 | 7.25 | 7.58 | 13.56 |
| 2023-12-31 | 67.5 | 11.5 | 6.53 | 8.47 |
| 2024-12-31 | 71.52 | 21.52 | 17.31 | 14.95 |
| 2025-12-31 | 71.14 | 15.06 | 20.13 | 24.31 |
Public data excerpt created by iPulse AI and published by Future Edge Group FZE. Source: eodhd. Snapshot retrieved 2026-09-22.
Use is subject to the iPulse AI Terms of Service and applicable source rights. Missing inputs are not estimated. Full access includes the remaining records, research and interactive tools.
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.